FDA

FDA approves roflumilast for COPD treatment

The FDA has approved a new treatment for people with worsening symptoms of severe chronic obstructive pulmonary disease (COPD), a lung disorder that makes breathing difficult.

The drug, roflumilast -- carrying the trade name Daliresp -- will be sold in pill form, unlike some other medications for COPD, which are inhaled.

Syndicate content